Trials / Terminated
TerminatedNCT05559541
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
A Multicenter, Open-Label, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK119 | AK119 is an anti-CD73 monoclonal antibody. |
| DRUG | AK104 | AK104 is an anti-PD-1 and CTLA-4 bispecific antibody. |
Timeline
- Start date
- 2022-12-15
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2022-09-29
- Last updated
- 2025-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05559541. Inclusion in this directory is not an endorsement.